Johnson & Johnson (JNJ) operating KPIs
JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3043% above fair value
$273.20−2.00 (-0.73%)
Close on Oct 30, 2026Market cap $658.38BP/E 31.7Yield 1.88%
Johnson & Johnson rISPERDAL CONSTA (risperidone) [reported separately through FY2022Q4] — International sales ($M) ($M)
Form 10-Q / 10-K Segment Note & Form 8-K EX-99.2 Segment Sales Schedule
Latest, FY2023
100
Period ended Dec 31, 2023
Change on a year earlier
+117.4%
46 in FY2022
History
8 years
Since FY2016
Sources
5
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | RISPERDAL CONSTA (risperidone) [reported separately through FY2022Q4] — International sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2023 | Dec 31, 2023 | 100 | +117.4% | Form 10-K (filed 2024-02-16) ↗ |
| FY2022 | Jan 1, 2023 | 46 | +76.9% | Form 10-K (filed 2024-02-16) ↗ |
| FY2021 | Jan 2, 2022 | 26 | -92.5% | Form 10-K (filed 2024-02-16) ↗ |
| FY2020 | Jan 3, 2021 | 346 | -7.5% | Form 10-K (filed 2023-02-16) ↗ |
| FY2019 | Dec 29, 2019 | 374 | -11.4% | Form 10-K (filed 2022-02-17) ↗ |
| FY2018 | Dec 30, 2018 | 422 | -5.2% | Form 10-K (filed 2021-02-22) ↗ |
| FY2017 | Dec 31, 2017 | 445 | -13.1% | Form 10-K (filed 2019-02-20) ↗ |
| FY2016 | Jan 1, 2017 | 512 | – | Form 10-K (filed 2019-02-20) ↗ |
Breakdown
What makes up risperdal consta (risperidone) [reported separately through fy2022q4] — international sales ($m)
Cite this data
StockData. (2026). Johnson & Johnson RISPERDAL CONSTA (risperidone) [reported separately through FY2022Q4] — International sales ($M) ($M), annual FY2016–FY2023 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/drug_risperdal_consta_intl
See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.